{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:37:28Z","timestamp":1787164648404,"version":"build-2736575974"},"reference-count":110,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2019.00326","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T07:26:02Z","timestamp":1579245962000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":66,"title":["Inflammatory Myopathy-Related Interstitial Lung Disease: From Pathophysiology to Treatment"],"prefix":"10.3389","volume":"6","author":[{"given":"Baptiste","family":"Hervier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurdag\u00fcl","family":"Uzunhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11926-018-0731-7","article-title":"Management of interstitial lung disease in patients with myositis specific autoantibodies","volume":"20","author":"Mecoli","year":"2018","journal-title":"Curr Rheumatol Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1183\/09031936.03.00026703","article-title":"Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis","volume":"22","author":"Cottin","year":"2003","journal-title":"Eur Respir J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1164\/rccm.200607-912OC","article-title":"Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes","volume":"175","author":"Park","year":"2007","journal-title":"Am J Respir Crit Care Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.rmed.2011.08.015","article-title":"Does the presence of connective tissue disease modify survival in patients with pulmonary fibrosis?","volume":"105","author":"Navaratnam","year":"2011","journal-title":"Respir Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.rmed.2018.02.024","article-title":"Distinctive characteristics and prognostic significance of interstitial pneumonia with autoimmune features in patients with chronic fibrosing interstitial pneumonia","volume":"137","author":"Yoshimura","year":"2018","journal-title":"Respir Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B9","first-page":"e51","article-title":"Response to: \u2018Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria' by Cavagna et al","volume":"77","author":"Lilleker","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O'Callaghan","year":"2018","journal-title":"Lancet Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal Muscle Involvement in Antisynthetase Syndrome","volume":"74","author":"Noguchi","year":"2017","journal-title":"JAMA Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1212\/WNL.0000000000001422","article-title":"Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy","volume":"84","author":"Stenzel","year":"2015","journal-title":"Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s40478-014-0154-2","article-title":"Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy","volume":"2","author":"Aouizerate","year":"2014","journal-title":"Acta Neuropathol Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1093\/brain\/awv192","article-title":"Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis","volume":"138","author":"Mescam-Mancini","year":"2015","journal-title":"Brain J Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"290797","DOI":"10.1155\/2014\/290797","article-title":"Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis","volume":"2014","author":"Labrador-Horrillo","year":"2014","journal-title":"J Immunol Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/acr.22498","article-title":"Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease","volume":"67","author":"Narang","year":"2015","journal-title":"Arthritis Care Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","author":"Aggarwal","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1177\/0961203312456751","article-title":"Distinct phenotypes in mixed connective tissue disease: subgroups and survival","volume":"21","author":"Szodoray","year":"2012","journal-title":"Lupus."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/art.38428","article-title":"Clinical and serologic correlates of anti-PM\/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients","volume":"66","author":"D'Aoust","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","article-title":"Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies","volume":"90","author":"De Lorenzo","year":"2018","journal-title":"Neurology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MD.0b013e31824d9cec","article-title":"Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease","volume":"91","author":"Rigolet","year":"2012","journal-title":"Medicine."},{"key":"B24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated Gene 5 antibody: expanding the clinical spectrum in North American patients with Dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","article-title":"Myopathy with antibodies to the signal recognition particle: clinical and pathological features","volume":"73","author":"Miller","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B27","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/ard.2005.040717","article-title":"Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jim.2012.07.019","article-title":"Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort","volume":"384","author":"Tarricone","year":"2012","journal-title":"J Immunol Methods."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/ard.2008.097162","article-title":"Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis","volume":"68","author":"Betteridge","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis","volume":"14","author":"Lundberg","year":"2018","journal-title":"Nat Rev Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur Respir J."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0139-2017","article-title":"State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances","volume":"27","author":"Sambataro","year":"2018","journal-title":"Eur Respir Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3899\/jrheum.150966","article-title":"A Multidisciplinary evaluation helps identify the antisynthetase syndrome in patients presenting as idiopathic interstitial pneumonia","volume":"43","author":"Chartrand","year":"2016","journal-title":"J Rheumatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1084\/jem.20161596","article-title":"Type I interferon-mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview","volume":"213","author":"Rodero","year":"2016","journal-title":"J Exp Med."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.900843","article-title":"Serum interferon-\u03b1 is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis","author":"Horai","year":"2014","journal-title":"Mod Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","article-title":"Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression","volume":"186","author":"Allenbach","year":"2016","journal-title":"Am J Pathol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3389\/fimmu.2019.01140","article-title":"The role of monocytes and macrophages in autoimmune diseases: a comprehensive review","volume":"10","author":"Ma","year":"2019","journal-title":"Front Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1164\/rccm.200509-1518OC","article-title":"A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18","volume":"173","author":"Prasse","year":"2006","journal-title":"Am J Respir Crit Care Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12931-018-0864-2","article-title":"Macrophages: friend or foe in idiopathic pulmonary fibrosis?","volume":"19","author":"Zhang","year":"2018","journal-title":"Respir Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/rheumatology\/kez185","article-title":"Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD","volume":"58","author":"Horiike","year":"2019","journal-title":"Rheumatology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13104-018-3146-7","article-title":"Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report","volume":"11","author":"Yamada","year":"2018","journal-title":"BMC Res Notes."},{"key":"B45","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1097\/BOR.0000000000000555","article-title":"Antisynthetase syndrome pathogenesis: knowledge and uncertainties","volume":"30","author":"Gallay","year":"2018","journal-title":"Curr Opin Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/annrheumdis-2011-200182","article-title":"Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study","volume":"71","author":"Chinoy","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/art.39059","article-title":"Nested case-control study of selected systemic autoimmune diseases in World Trade Center rescue\/recovery workers","volume":"67","author":"Webber","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1136\/annrheumdis-2017-211174","article-title":"Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case-control study","volume":"76","author":"Svensson","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1002\/art.22790","article-title":"Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis","volume":"56","author":"Levine","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B50","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20020186","article-title":"Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells","volume":"196","author":"Howard","year":"2002","journal-title":"J Exp Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1126\/science.1252943","article-title":"Human tRNA synthetase catalytic nulls with diverse functions","volume":"345","author":"Lo","year":"2014","journal-title":"Science."},{"key":"B52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1615\/CritRevImmunol.2018025744","article-title":"Immunopathogenesis of the Anti-Synthetase Syndrome","volume":"38","author":"Gayed","year":"2018","journal-title":"Crit Rev Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","article-title":"Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups","volume":"75","author":"Rothwell","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e98824","DOI":"10.1371\/journal.pone.0098824","article-title":"Prognostic factors for myositis-associated interstitial lung disease","volume":"9","author":"Fujisawa","year":"2014","journal-title":"PLoS ONE."},{"key":"B55","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/thx.2006.069237","article-title":"Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset","volume":"63","author":"Tillie-Leblond","year":"2008","journal-title":"Thorax."},{"key":"B56","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13613-018-0433-3","article-title":"Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study","volume":"8","author":"Vuillard","year":"2018","journal-title":"Ann Intensive Care."},{"key":"B57","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.rmed.2011.05.006","article-title":"HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody","volume":"105","author":"Tanizawa","year":"2011","journal-title":"Respir Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00296-016-3571-7","article-title":"Outcome and prognostic factors in a French cohort of patients with myositis-associated interstitial lung disease","volume":"36","author":"Obert","year":"2016","journal-title":"Rheumatol Int."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3899\/jrheum.111604","article-title":"Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use","volume":"39","author":"Stanciu","year":"2012","journal-title":"J Rheumatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1148\/radiol.2213010158","article-title":"Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT","volume":"221","author":"MacDonald","year":"2001","journal-title":"Radiology."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur Respir J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1152\/japplphysiol.01060.2018","article-title":"Diaphragm shear modulus reflects transdiaphragmatic pressure during isovolumetric inspiratory efforts and ventilation against inspiratory loading","volume":"126","author":"Bachasson","year":"2019","journal-title":"J Appl Physiol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.nmd.2004.09.006","article-title":"Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies","volume":"15","author":"Teixeira","year":"2005","journal-title":"Neuromuscul Disord."},{"key":"B67","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s10067-015-3023-x","article-title":"Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)","volume":"34","author":"Rojas-Serrano","year":"2015","journal-title":"Clin Rheumatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/art.23571","article-title":"Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology","volume":"59","author":"Fathi","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1164\/rccm.201105-0840OC","article-title":"Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference","volume":"183","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","article-title":"Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group","volume":"46","author":"Trallero-Aragu\u00e1s","year":"2016","journal-title":"Semin Arthritis Rheum."},{"key":"B75","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/rheumatology\/kew426","article-title":"Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s10067-018-4353-2","article-title":"Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease","volume":"38","author":"Cobo-Ib\u00e1\u00f1ez","year":"2019","journal-title":"Clin Rheumatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1365-2796.2011.02459.x","article-title":"KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis","volume":"271","author":"Fathi","year":"2012","journal-title":"J Intern Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"R78","DOI":"10.1186\/ar2276","article-title":"Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes","volume":"9","author":"Koenig","year":"2007","journal-title":"Arthritis Res Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/08916930600623791","article-title":"In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease","volume":"39","author":"La Corte","year":"2006","journal-title":"Autoimmunity."},{"key":"B80","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/art.24372","article-title":"Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis","volume":"61","author":"Le Goff","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B81","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1191\/0961203305lu2158oa","article-title":"Polymyositis\/dermatomyositis-associated lung disease: analysis of a series of 81 patients","volume":"14","author":"Selva-O'Callaghan","year":"2005","journal-title":"Lupus."},{"key":"B82","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/LBR.0b013e3181ca6b6c","article-title":"Spontaneous pneumomediastinum in a patient with facial rash","volume":"17","author":"Machuca","year":"2010","journal-title":"J Bronchol Interv Pulmonol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1378\/chest.07-0286","article-title":"A 34-year-old man with amyopathic dermatomyositis and rapidly progressive dyspnea with facial swelling. Diagnosis: pneumomediastinum and subcutaneous emphysema secondary to amyopathic dermatomyositis-associated interstitial lung disease","volume":"132","author":"Powell","year":"2007","journal-title":"Chest."},{"key":"B84","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10067-015-3001-3","article-title":"Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum","volume":"35","author":"Ma","year":"2016","journal-title":"Clin Rheumatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1016\/j.vaccine.2018.06.062","article-title":"Response to pneumococcal vaccine in interstitial lung disease patients: influence of systemic immunosuppressive treatment","volume":"36","author":"Kuronuma","year":"2018","journal-title":"Vaccine."},{"key":"B86","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/1756-185X.13255","article-title":"Opportunistic infections in patients with idiopathic inflammatory myopathies","volume":"21","author":"Redondo-Benito","year":"2018","journal-title":"Int J Rheum Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B88","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/thoraxjnl-2016-208638","article-title":"The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial","volume":"72","author":"Dowman","year":"2017","journal-title":"Thorax."},{"key":"B89","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1378\/chest.08-0754","article-title":"Serum albumin concentration and waiting list mortality in idiopathic interstitial pneumonia","volume":"135","author":"Zisman","year":"2009","journal-title":"Chest."},{"key":"B90","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1002\/art.21240","article-title":"Treatment of antisynthetase-associated interstitial lung disease with tacrolimus","volume":"52","author":"Wilkes","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B92","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","article-title":"Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis","volume":"46","author":"Yamasaki","year":"2007","journal-title":"Rheumatology."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3899\/jrheum.161217","article-title":"Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort","volume":"44","author":"Sharma","year":"2017","journal-title":"J Rheumatol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"R149","DOI":"10.1186\/ar4332","article-title":"Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome","volume":"15","author":"Marie","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1164\/ajrccm.164.7.2103110","article-title":"Polymyositis-dermatomyositis-associated interstitial lung disease","volume":"164","author":"Douglas","year":"2001","journal-title":"Am J Respir Crit Care Med."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease","author":"Huapaya","year":"2019","journal-title":"Chest."},{"key":"B97","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Mira-Avendano","year":"2013","journal-title":"Respir Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","article-title":"The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis","volume":"54","author":"Kurita","year":"2015","journal-title":"Rheumatol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","article-title":"Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease","volume":"154","author":"Huapaya","year":"2019","journal-title":"Respir Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"e0133702","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS ONE."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/rheumatology\/kew195","article-title":"Rituximab in autoimmune connective tissue disease-associated interstitial lung disease","volume":"55","author":"Sharp","year":"2016","journal-title":"Rheumatol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"Doyle","year":"2018","journal-title":"J Rheumatol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/rheumatology\/kew146","article-title":"Rituximab in the treatment of inflammatory myopathies: a review","volume":"56","author":"Fasano","year":"2017","journal-title":"Rheumatol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","article-title":"Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody","volume":"73","author":"Zou","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B106","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.healun.2016.12.013","article-title":"Survival and outcomes after lung transplantation for non-scleroderma connective tissue-related interstitial lung disease","volume":"36","author":"Courtwright","year":"2017","journal-title":"J Heart Lung Transplant."},{"key":"B110","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1016\/j.transproceed.2014.09.163","article-title":"Is lung transplantation a valuable therapeutic option for patients with pulmonary polymyositis? Experiences from the Leuven transplant cohort","volume":"46","author":"Ameye","year":"2014","journal-title":"Transplant Proc."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00326\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T07:26:05Z","timestamp":1579245965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00326\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":110,"alternative-id":["10.3389\/fmed.2019.00326"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2019.00326","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"article-number":"326"}}